Zhen, Jamie
Marshall, John K.
Nguyen, Geoffrey C.
Atreja, Ashish
Narula, Neeraj http://orcid.org/0000-0002-1536-8436
Funding for this research was provided by:
Crohn's and Colitis Canada
Article History
Received: 2 November 2020
Accepted: 6 January 2021
First Online: 15 January 2021
Compliance with ethical standards
: No other author has any relevant conflicts of interest.
: The RxUniverse software platform and HealthPROMISE digital therapeutic are licensed technologies from Icahn School of Medicine at Mount Sinai to Rx.Health, Inc. (New York, NY). Ashish Atreja owns stock in Rx.Health and have recused himself from data analysis. Neeraj Narula holds a McMaster University Department of Medicine Internal Career Award. Neeraj Narula has received honoraria from Janssen, Abbvie, Takeda, Pfizer, Merck, Sandoz, Novartis, and Ferring.John Marshall receives honoraria as a speaker and/or consultant from AbbVie, Allergan, Amgen, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, Lilly, Lupin, Novartis, Paladin, Pfizer, Pharmascience, Procter & Gamble, Roche, Shire, Takeda, and Teva.
Free to read: This content has been made available to all.